专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150177246A1 FUSION GENE OF CEP55 GENE AND RET GENE 审中-公开
标题翻译： CEP55基因和RET基因的融合基因
公开(公告)号：US20150177246A1
公开(公告)日：2015-06-25
申请号：US14417052
申请日：2013-07-23
申请人： NATIONAL CANCER CENTER , LSIP, LLC
发明人： Tatsuhiro Shibata , Fumie Hosoda
IPC分类号： G01N33/574 , C07K16/32 , C07K14/82 , C12Q1/68 , C12N9/12
CPC分类号： G01N33/5748 , C07K14/4702 , C07K14/71 , C07K14/82 , C07K16/32 , C07K2319/00 , C12N9/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y207/10001 , G01N33/574 , G01N33/57446 , G01N2800/52
摘要： In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of diffuse-type gastric cancer. As a result, in-frame fusion transcripts between the CEP55 gene and the RET gene were identified. It was also found that said gene fusions induce activation of RET protein, thereby causing canceration of cells. Further, it was demonstrated that the RET protein activation and canceration caused by said gene fusion can be suppressed by using a RET tyrosine kinase inhibitor, and that treatments with a RET tyrosine kinase inhibitor are effective in patients with detection of said gene fusion.
摘要翻译：为了鉴定可以作为预测癌症药物治疗有效性的指标的基因，并提供用于预测用于靶向所述基因的药物治疗有效性的新方法，对扩散型胃癌进行转录组测序。结果，鉴定了CEP55基因和RET基因之间的帧内融合转录本。还发现所述基因融合物诱导RET蛋白的激活，从而引起细胞癌变。此外，通过使用RET酪氨酸激酶抑制剂可以抑制由所述基因融合引起的RET蛋白活化和癌变，并且用RET酪氨酸激酶抑制剂进行治疗对于检测所述基因融合的患者是有效的。

2. 发明申请

US20140286978A1 CYTOTOXIC T LYMPHOCYTE INDUCER 审中-公开
标题翻译： CYTOTOXIC T淋巴细胞诱导因子
公开(公告)号：US20140286978A1
公开(公告)日：2014-09-25
申请号：US14117575
申请日：2012-04-24
申请人： TOKYO INSTITUTE OF TECHNOLOGY , LSIP, LLC , SAITAMA MEDICAL UNIVERSITY
发明人： Hiroshi Handa , Masaaki Kawano , Masanori Matsui
IPC分类号： A61K39/145 , A61K39/00
CPC分类号： A61K39/145 , A61K35/76 , A61K38/162 , A61K39/0011 , A61K39/12 , A61K2039/5258 , A61K2039/55561 , C12N2710/22023 , C12N2710/22034 , C12N2760/16134
摘要： The invention provides a cytotoxic T lymphocyte inducer comprising a virus-like particle composed of VP1 of simian virus 40. The T cell epitope peptide is inserted into a DE loop and/or an HI loop of the VP1.
摘要翻译：本发明提供了包含由猿猴病毒40的VP1组成的病毒样颗粒的细胞毒性T淋巴细胞诱导剂.T细胞表位肽插入到VP1的DE环和/或HI环中。

3. 发明申请

US20170014338A1 NASAL VACCINE FOR STREPTOCOCCUS PNEUMONIAE 有权
公开(公告)号：US20170014338A1
公开(公告)日：2017-01-19
申请号：US15119335
申请日：2015-02-16
申请人： LSIP, LLC
发明人： Yoshikazu YUKI , Hiroshi KIYONO , Kazunari AKIYOSHI , Shinichi SAWADA
IPC分类号： A61K9/00 , A61K47/36 , A61K39/09
CPC分类号： A61K9/0043 , A61K9/06 , A61K39/092 , A61K47/36 , A61K2039/543 , A61K2039/552 , A61K2039/55555
摘要： The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.
摘要翻译：本发明提供了一种用于肺炎链球菌的鼻疫苗及其制备方法。用于灵长类动物的鼻用疫苗制剂包括作为侧链的PspA复合物，即疫苗抗原和其中加入疏水性胆固醇的纳米凝胶，具有具有氨基的支链淀粉。此外，本发明提供了用于灵长类动物的鼻用疫苗制剂的制备方法。

4. 发明申请

US20160195535A1 METHOD FOR DETECTING PROSTATIC BASAL CELLS 审中-公开
标题翻译：检测前列腺细胞的方法
公开(公告)号：US20160195535A1
公开(公告)日：2016-07-07
申请号：US14653562
申请日：2013-12-18
申请人： NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY , LSIP, LLC
发明人： Shigetsugu Hatakeyama , Shinya Tanaka
IPC分类号： G01N33/574 , C07K16/18
CPC分类号： G01N33/57434 , C07K16/18 , G01N2333/435 , G01N2333/4703 , G01N2333/4742 , G01N2333/4748
摘要： The purpose of the present invention is to provide a method for detecting prostatic basal cells by searching for molecules that are expressed specifically in prostatic basal cells and analyzing said molecules. The problem can be solved using a method for detecting prostatic basal cells that is characterized by using immunohistochemical staining to visualize the expression of TRIM29 (Tripartite motif-containing protein 29) protein in prostatic basal cells.
摘要翻译：本发明的目的是提供一种通过搜索在前列腺基底细胞中特异性表达并分析所述分子的分子来检测前列腺基底细胞的方法。使用检测前列腺基底细胞的方法可以解决问题，其特征在于使用免疫组织化学染色来观察前列腺基底细胞中TRIM29（含三聚体基序的蛋白29）蛋白的表达。

5. 发明授权

US09176236B2 Device for measuring radiation intensity of small sealed radiation source for cancer therapy 有权
标题翻译：用于测量癌症治疗的小型密封辐射源的辐射强度的装置
公开(公告)号：US09176236B2
公开(公告)日：2015-11-03
申请号：US14434374
申请日：2013-10-02
申请人： THE UNIVERSITY OF TOKUSHIMA , LSIP, LLC
发明人： Minoru Sakama , Hitoshi Ikushima , Takaharu Yamada , Hisashi Takai , Teruyoshi Ichiraku
IPC分类号： A61N5/10 , G01T1/161
CPC分类号： G01T1/161 , A61N5/1001 , A61N5/1048 , A61N5/1075
摘要： The invention provides a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy that is capable of measuring multiple cartridges. The apparatus includes a device for setting up multiple cartridges and a device for measuring the radiation intensities of radiation passing through a narrow slit. Radiation is emitted from multiple radiation sources and the radiation measurement device moves simultaneously together with the slit along with the side of cartridge holding device while scanning the radiation intensities. Included is a radiation detection scanning device for measuring radiation intensities for each of the radiation sources passing through the narrow slit, and a slit shielding system for restricting radiation originated originating from both the side neighboring radiation sources. The moving device is configured move the radiation measurement device along the direction in the side of cartridge where multiple radiation sources are lined up close to each other.
摘要翻译：本发明提供了一种能够测量多个盒的用于癌症治疗的小型密封辐射源的辐射强度测量装置。该装置包括用于设置多个盒的装置和用于测量通过狭窄狭缝的辐射的辐射强度的装置。辐射从多个辐射源发射，并且辐射测量装置在扫描辐射强度的同时与狭缝一起同时与盒保持装置的侧面一起移动。包括用于测量通过窄狭缝的每个辐射源的辐射强度的辐射检测扫描装置，以及用于限制源自两个相邻辐射源的辐射的狭缝屏蔽系统。移动装置被配置为沿着盒的侧面上的方向移动辐射测量装置，其中多个辐射源彼此靠近排列。

6. 发明申请

US20150241568A1 DEVICE FOR MEASURING RADIATION INTENSITY OF SMALL SEALED RADIATION SOURCE FOR CANCER THERAPY 有权
标题翻译：用于测量癌症治疗小切口辐射源辐射强度的装置
公开(公告)号：US20150241568A1
公开(公告)日：2015-08-27
申请号：US14434374
申请日：2013-10-02
申请人： THE UNIVERSITY OF TOKUSHIMA , LSIP, LLC
发明人： Minoru Sakama , Hitoshi Ikushima , Takaharu Yamada , Hisashi Takai , Teruyoshi Ichiraku
IPC分类号： G01T1/161 , A61N5/10
CPC分类号： G01T1/161 , A61N5/1001 , A61N5/1048 , A61N5/1075
摘要： Provided is a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy capable of measuring multiple cartridges efficiently and rapidly.A radiation intensity measuring apparatus for radiation sources S in the state that the multiple radiation sources S are packed in a seed cartridge SC of a cartridge C, includes holding means 10 capable of holding the multiple cartridges C; radiation intensity measuring means 30 for measuring intensity of the radiation emitted from the multiple radiation sources S; and moving means 20 for moving the radiation intensity measuring means 30 toward or away from the holding means 10, and the radiation intensity measuring means 30 includes: a sensor 31 for measuring radiation intensity, and a shielding member 35 having a slit 35h provided for restricting radiation irradiated to the sensor 31; and the moving means 20 is configured to be able to relatively move the radiation intensity measuring means 30 along the direction in which the multiple radiation sources S are arranged in the measurement state.
摘要翻译：提供了用于癌细胞治疗的小型密封辐射源的每个辐射强度测量装置，其能够有效且快速地测量多个盒。在多个辐射源S被包装在盒C的种子盒SC中的状态下的用于辐射源S的辐射强度测量装置包括能够保持多个盒C的保持装置10; 用于测量从多个辐射源S发射的辐射的强度的辐射强度测量装置30; 以及用于使辐射强度测量装置30朝向或远离保持装置10移动的移动装置20，并且辐射强度测量装置30包括：用于测量辐射强度的传感器31和具有狭缝35h的屏蔽构件35，照射到传感器31的辐射; 并且移动装置20被构造成能够使辐射强度测量装置30沿着测量状态下的多个辐射源S的排列方向相对移动。

7. 发明申请

US20150198598A1 KIT FOR DIAGNOSING MALIGNANT MELANOMA 有权
标题翻译：用于诊断恶性肿瘤的试剂盒
公开(公告)号：US20150198598A1
公开(公告)日：2015-07-16
申请号：US14408883
申请日：2013-06-17
申请人： NATIONAL CANCER CENTER , LSIP, LLC
发明人： Tetsuya Nakatsura , Keigo Saito
IPC分类号： G01N33/574 , C07K16/30 , C07K16/22
CPC分类号： G01N33/5743 , C07K16/18 , C07K16/22 , C07K16/303 , C07K16/3053 , C07K2319/00 , C12N5/16 , C12N2510/02 , G01N33/577 , G01N2333/4722 , G01N2333/4727
摘要： Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
摘要翻译：提供了用于以高再现性诊断的试剂盒，所述试剂盒通过制备针对GPC3的单克隆抗体和针对SPARC的单克隆抗体而产生，其针对市售和常用抗体的质量稳定性优异，并且使用这些抗体。

8. 发明申请

US20150191791A1 FGFR2 FUSION GENE 审中-公开
标题翻译： FGFR2融合基因
公开(公告)号：US20150191791A1
公开(公告)日：2015-07-09
申请号：US14412986
申请日：2013-07-05
申请人： NATIONAL CANCER CENTER , LSIP, LLC
发明人： Tatsuhiro Shibata
IPC分类号： C12Q1/68 , C07K16/40 , C07K16/28 , C12N9/12 , G01N33/573
CPC分类号： C12Q1/6886 , C07K14/47 , C07K14/71 , C07K16/2863 , C07K16/40 , C07K2317/76 , C07K2319/00 , C12N9/12 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Y207/10001 , G01N33/5011 , G01N33/573 , G01N33/574 , G01N2333/912 , G01N2800/52
摘要： In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of biliary tract cancer. As a result, in-frame fusion transcripts between the FGFR2 gene and other gene (BICC1 or AHCYL1 gene) were identified. It was also found that said gene fusions induce activation of FGFR2 protein, thereby causing canceration of cells. Further, it was demonstrated that the FGFR2 protein activation and canceration caused by said gene fusions can be suppressed by using an FGFR2 inhibitor, and that treatments with an FGFR2 inhibitor are effective in patients with detection of said gene fusions.
摘要翻译：为了鉴定可以作为预测癌症药物治疗有效性的指标的基因，并提供用于预测用靶向所述基因的药物治疗有效性的新方法，对胆道癌进行转录组测序。因此，鉴定了FGFR2基因与其他基因（BICC1或AHCYL1基因）之间的帧内融合转录本。还发现所述基因融合物诱导FGFR2蛋白的激活，从而引起细胞癌变。此外，通过使用FGFR2抑制剂可以抑制由所述基因融合引起的FGFR2蛋白激活和癌变，并且用FGFR2抑制剂进行治疗对于检测所述基因融合体的患者是有效的。

9. 发明申请

US20150057335A1 NOVEL FUSION GENES IDENTIFIED IN LUNG CANCER 审中-公开
标题翻译：在肺癌中鉴定出新的融合基因
公开(公告)号：US20150057335A1
公开(公告)日：2015-02-26
申请号：US14463894
申请日：2014-08-20
申请人： National Cancer Center , National Center for Global Health and Medicine , LSIP, LLC
发明人： Takashi Kohno , Koji Tsuta , Kazuki Yasuda
IPC分类号： C12Q1/68 , A61K31/517 , G01N33/50 , C07K14/475 , C07K14/47 , C12N15/113 , C07K14/705
CPC分类号： C12Q1/6886 , A61K31/517 , C07K14/47 , C07K14/4756 , C07K14/70596 , C07K2319/00 , C12N9/12 , C12N9/93 , C12N15/113 , C12N15/1135 , C12N15/62 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N2500/04 , G01N2500/10
摘要： [PROBLEMS] To identify mutations that can serve as indicators for predicting the effectiveness of drug treatments in cancers such as lung cancer; to provide a means for detecting said mutations; and to provide a means for identifying, based on said mutations, patients with cancer or subjects with a risk of cancer, in which drugs targeting genes having said mutations or proteins encoded by said genes show a therapeutic effect.[MEANS FOR SOLVING] A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an EZR-ERBB4 fusion polynucleotide, a KIAA1468-RET fusion polynucleotide, a TRIM24-a BRAF fusion polynucleotide, a CD74-NRG1 fusion polynucleotide, and an SLC3A2-NRG1 fusion polynucleotide, or a polypeptide encoded thereby, in an isolated sample from a subject with cancer.
摘要翻译： [问题]识别可用作预测癌症如肺癌药物治疗有效性的指标的突变; 以提供检测所述突变的手段; 并且提供一种用于基于所述突变识别具有癌症的患者或具有癌症风险的受试者的方法，其中靶向具有所述突变的基因的基因或由所述基因编码的蛋白质具有治疗效果。用于检测癌症的负责突变（驱动突变）的基因融合方法，所述方法包括检测EZR-ERBB4融合多核苷酸，KIAA1468-RET融合多核苷酸，TRIM24中的任一种的步骤一种BRAF融合多核苷酸，一种CD74-NRG1融合多核苷酸和一种SLC3A2-NRG1融合多核苷酸，或由此编码的多肽，来自患有癌症的受试者的分离样品。

10. 发明申请

US20150031872A1 METHOD FOR SCREENING ANTICANCER DRUGS, AND ANTICANCER DRUG THAT INDUCES CELL DEATH AND USES SUBSTANCE THAT INCREASES GRANZYME M ACTIVITY AS ACTIVE INGREDIENT 审中-公开
标题翻译：用于筛选抗生素药物的方法，以及诱发细胞死亡的抗生素药物和使用作为活性成分的GRANZYME M活性的物质
公开(公告)号：US20150031872A1
公开(公告)日：2015-01-29
申请号：US14384542
申请日：2013-03-13
申请人： LSIP, LLC
发明人： Shunichiro Kubota , Motohiko Sato , Liyun Wang
IPC分类号： C12Q1/37 , G01N33/50 , A61K31/7068
CPC分类号： C12Q1/37 , A61K31/7068 , A61K33/24 , G01N33/5011 , G01N33/57411 , G01N33/57426 , G01N2333/96436 , G01N2500/00 , G01N2500/04 , G01N2500/10 , G01N2510/00
摘要： The purpose of the present invention is to provide a method for screening anticancer drugs that use novel treatment mechanisms, and an anticancer drug that induces cell death and uses a substance that increases the activity of granzyme M as an active ingredient. This method for screening anticancer drugs comprises: a step for administering test substances to cancer cells; a step for detecting the activity of granzyme M in which cancer cells are expressed, and selecting test substances for which an increase in activity has been verified; and/or a step for detecting the presence or absence of cancer cell death induced by the activation of granzyme M in which cancer cells are expressed, and selecting test substances for which cell death has been verified.
摘要翻译：本发明的目的是提供一种筛选使用新型治疗机制的抗癌药物的方法，以及诱导细胞死亡的抗癌药物，并且使用增加粒酶M作为活性成分的活性的物质。用于筛选抗癌药物的方法包括：向癌细胞施用测试物质的步骤; 检测其中表达癌细胞的颗粒酶M的活性的步骤，以及选择已经验证了活性增加的测试物质; 和/或用于检测由表达癌细胞的粒酶M的活化引起的癌细胞死亡的存在或不存在的步骤，以及选择已经证实细胞死亡的测试物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式